Table 1.
Clinical characteristics of the study population (n = 43).
| BRAFi | BRAFi+MEKi | BRAFi+PD-1 antibody | Total | |
|---|---|---|---|---|
| N = 12 | N = 12 | N = 19 | N = 43 | |
| Sex—no. (%) | ||||
| Male | 5 (41.7) | 6 (50.0) | 13 (68.4) | 24 (55.8) |
| Female | 7 (58.3) | 6 (50.0) | 6 (31.6) | 19 (44.2) |
| Median (range) age—years | 52 (29–55) | 44 (27–63) | 49 (33–67) | 47 (27–67) |
| Performance status—no. (%) | ||||
| 0 | 1 (8.3) | 9 (75.0) | 13 (68.4) | 23 (53.5) |
| 1 | 10 (83.3) | 2 (16.7) | 6 (31.6) | 18 (41.9) |
| 2 | 1 (8.3) | 1 (8.3) | 0 | 2 (4.6) |
| LDH—no. (%) | ||||
| <ULN | 7 (58.3) | 9 | 14 (73.7) | 32 (74.4) |
| >ULN | 5 (41.7) | 3 (25.0) | 5 (26.3) | 11 (25.6) |
| Disease stage (AJCC#7)—no. (%) | ||||
| M1a | 2 (16.7) | 3 (25.0) | 9 (47.4) | 14 (32.6) |
| M1b | 3 (25.0) | 4 (33.3) | 5 (26.3) | 12 (27.9) |
| M1c | 6 (50.0) | 4 (33.3) | 2 (10.5) | 12 (27.9) |
| M1d | 1 (8.3) | 1 (8.3) | 3 (15.8) | 5 (11.6) |
| Disease site—no. (%) | ||||
| ≤3 | 4 (33.3) | 7 (58.3) | 12 (63.2) | 23 (53.5) |
| >3 | 8 (66.7) | 5 (41.7) | 7 (36.8) | 20 (46.5) |
| Brain metastases—no. (%) | ||||
| Yes | 1 (8.3) | 1 (8.3) | 3 (15.8) | 5 (11.7) |
| No | 11 (91.7) | 11 (91.7) | 16 (84.2) | 38 (88.3) |
| Regime—no. (%) | ||||
| Vemurafenib | 12 (100.0) | - | - | 12 (27.9) |
| Dabrafenib+trametinib | - | 11 (91.7) | - | 11 (25.6) |
| Vemurafenib+cobimetinib | - | 1 (8.3) | - | 1 (2.3) |
| Vemurafenib+pembrolizumab | - | - | 19 (100) | 19 (44.2) |
| Basic liver function—no. (%) | ||||
| Liver metastasis | 6 (50.0) | 5 (41.7) | 5 (26.3) | 16 (37.2) |
| Hepatitis B-antigen–positive. | 0 | 0 | 1 (5.3) | 1 (2.3) |
| Normal | 6 (50.0) | 7 (58.3) | 13 (68.4) | 26 (60.5) |
| Line of therapy—no. (%) | ||||
| 1 | 4 (33.3) | 4 (33.3) | 11 (57.9) | 19 (44.2) |
| 2 | 6 (50.0) | 6 (50.0) | 7 (36.8) | 19 (44.2) |
| 3 | 2 (16.7) | 1 (8.3) | 1 (5.3) | 4 (9.3) |
| 4 | 0 | 1 (8.3) | 0 | 1 (2.3) |
LDH, lactate dehydrogenase; ULN, upper normal limit; BRAFi, BRAF inhibitor; MEKi, MEK inhibitor.